Research programme: red blood cell therapeutics - Rubius Therapeutics
Alternative Names: aAPC; RCT-Rubius; RCT™; Red Cell Therapeutic Artificial Antigen-Presenting Cell; Red-Cell Therapeutic; RTX uricase; RTX-aAPCs; RTX-CBSLatest Information Update: 11 Aug 2023
At a glance
- Originator Rubius Therapeutics
- Developer Rubius Therapeutics [CEASED]
- Class Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Blood cell replacements; Cell replacements; Enzyme replacements; Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer; Gout; Homocystinuria; Type 1 diabetes mellitus
Most Recent Events
- 31 Dec 2022 Discontinued - Preclinical for Autoimmune disorders in USA (Parenteral) (Rubius Therapeutics website, December 2022)
- 31 Dec 2022 Discontinued - Preclinical for Cancer in USA (Parenteral) (Rubius Therapeutics website, December 2022)
- 31 Dec 2022 Discontinued - Preclinical for Gout in USA (Parenteral) (Rubius Therapeutics website, December 2022)